Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

(2023) Jianming Xu et al.   LANCET ONCOLOGY

Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis

(2023) Kenneth O'Byrne et al.   LUNG CANCER

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis

(2023) Muyesar Alifu et al.   Frontiers in Oncology

RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.

(2022) Li Zhang et al.   JOURNAL OF CLINICAL ONCOLOGY

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

(2022) Lin Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis

(2022) Xiao Zhang et al.   World Journal of Surgical Oncology

Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis

(2022) Zi-Chun Li et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

(2022) S. Qin et al.   ANNALS OF ONCOLOGY

Efficacy and safety of nivolumab for advanced/recurrent non-small-cell lung cancer: an up-to-date meta-analysis of large-scale phase III randomized controlled trials

(2022) Hong Zhang et al.   Future Oncology

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

(2022) Caicun Zhou et al.   Journal of Thoracic Oncology

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis

(2022) Maryam Noori et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

(2021) Lihui Liu et al.   Journal of Thoracic Oncology

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

(2021) Jie Wang et al.   JAMA Oncology

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review

(2021) Caterina Arru et al.   ADVANCES IN THERAPY

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

(2021) Shun Lu et al.   Journal of Thoracic Oncology

Tislelizumab: First Approval

(2020) Arnold Lee et al.   DRUGS

Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

(2020) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

(2020) Jayesh Desai et al.   Journal for ImmunoTherapy of Cancer

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

(2020) Lin Shen et al.   Journal for ImmunoTherapy of Cancer

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

(2020) Dingwei Ye et al.   CANCER SCIENCE

Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)

(2020) Si-Yang Liu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients

(2020) Zhijie Wang et al.   LUNG CANCER

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation

(2020) Elizabeth C. Paver et al.   PATHOLOGY

PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy

(2019) Arash Salmaninejad et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

(2018) Tong Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

(2017) Hyun Tae Lee et al.   Scientific Reports

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer

(2016) Jamaal A Rehman et al.   MODERN PATHOLOGY

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE